Related Experiment Video
Updated: Jan 28, 2026

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model
Sarah Walker1,2, Miriam Wankell3, Vikki Ho1
1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, Australia.
Abstract:
Liver cancer is a poor prognosis cancer with limited treatment options. To develop a new therapeutic approach, we derived HCC cells from a known model of murine hepatocellular carcinoma (HCC). We treated adiponectin (APN) knock-out mice with the carcinogen diethylnitrosamine, and the resulting tumors were 7-fold larger than wild-type controls. Tumors were disassociated from both genotypes and their growth characteristics evaluated. A52 cells from APN KO mice had the most robust growth in vitro and in vivo, and presented with pathology similar to the parental tumor. All primary tumors and cell lines exhibited activity of the mammalian target of Rapamycin (mTOR) and Src pathways. Subsequent combinatorial treatment, with the mTOR inhibitor Rapamycin and the Src inhibitor Dasatinib reduced A52 HCC growth 29-fold in vivo. Through protein and histological analyzes we observed activation of these pathways in human HCC, suggesting that targeting both mTOR and Src may be a novel approach for the treatment of HCC.
Insights
Adiponectin deficiency exacerbates liver cancer (hepatocellular carcinoma) growth. Combining mTOR and Src inhibitors significantly reduced tumor growth, suggesting a novel therapeutic strategy for hepatocellular carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) presents a poor prognosis with limited therapeutic options.
- Adiponectin (APN) plays a role in regulating cell growth and metabolism.
- Investigating the role of APN in HCC development and identifying novel therapeutic targets is crucial.
Purpose of the Study:
- To investigate the impact of adiponectin deficiency on hepatocellular carcinoma (HCC) development and progression.
- To identify potential therapeutic targets for HCC by analyzing activated signaling pathways.
- To evaluate the efficacy of combined inhibition of mTOR and Src pathways in HCC treatment.
Main Methods:
- Generated hepatocellular carcinoma (HCC) cells from adiponectin (APN) knock-out and wild-type murine models.
- Administered carcinogen diethylnitrosamine to induce tumors.
- Evaluated tumor growth characteristics in vitro and in vivo.
- Assessed the activity of mammalian target of Rapamycin (mTOR) and Src pathways.
- Conducted combinatorial treatment with mTOR inhibitor Rapamycin and Src inhibitor Dasatinib.
Main Results:
- Adiponectin knock-out mice developed significantly larger tumors (7-fold) compared to wild-type controls.
- Derived A52 HCC cells from APN KO mice exhibited robust in vitro and in vivo growth with similar pathology to parental tumors.
- Both primary tumors and cell lines showed activation of mammalian target of Rapamycin (mTOR) and Src pathways.
- Combined treatment with Rapamycin and Dasatinib reduced A52 HCC growth by 29-fold in vivo.
- Protein and histological analyses confirmed mTOR and Src pathway activation in human HCC samples.
Conclusions:
- Adiponectin deficiency promotes hepatocellular carcinoma (HCC) growth.
- The mammalian target of Rapamycin (mTOR) and Src pathways are activated in HCC.
- Combined inhibition of mTOR and Src represents a promising novel therapeutic strategy for treating HCC.
More Related Videos
05:06A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Restriction Enzymes
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
PI3K/mTOR/AKT Signaling Pathway
Growth Models with Integration: Problem Solving
Exponential Equations for Modeling Growth